TP53 and prostate carcinoma: We chose to orthogonally validate our proteomic data set and IPA interpretations using a luciferase reporter system for MYC binding elements, reasoning that PC-3 cells are functionally considered P53 null [90] and that advanced prostate cancers frequently overexpress c-myc [91].